ONCASPAR Drug Profile

Summary for Tradename: ONCASPAR

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ONCASPAR

Recent Clinical Trials for ONCASPAR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Dana-Farber Cancer Institute	PHASE2
City of Hope Medical Center	Phase 1
M.D. Anderson Cancer Center	Phase 1/Phase 2

See all ONCASPAR clinical trials

Pharmacology for ONCASPAR

Established Pharmacologic Class	Asparagine-specific Enzyme
Chemical Structure	Asparaginase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ONCASPAR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ONCASPAR Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ONCASPAR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2036-12-09	Patent claims search
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2037-07-18	Patent claims search
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2033-05-03	Patent claims search
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2037-09-01	Patent claims search
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2035-09-14	Patent claims search
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411		2036-07-08	Patent claims search

Market Dynamics and Financial Trajectory for ONCASPAR (Pegaspargase)

Last updated: February 20, 2026

What is ONCASPAR's Current Market Position?

ONCASPAR (pegaspargase) is a biologic drug used primarily in the treatment of acute lymphoblastic leukemia (ALL). It is a pegylated form of asparaginase, deriving from Escherichia coli. It received FDA approval in 2018 for adult and pediatric patients with ALL who have hypersensitivity to E. coli-derived asparaginase. The drug's market is driven by its niche role in chemotherapy protocols and the rising incidence of leukemia globally.

What are the Key Market Drivers and Barriers?

Drivers:

• Increasing prevalence of ALL: Estimated at 6.4 cases per 100,000 annually in high-income countries, with rising incidence in pediatric populations.
• Growth in combination therapy protocols: Clinicians favor biologics like ONCASPAR in multi-drug regimens for better tolerability.
• Regulatory approvals: Expanded indications in certain regions bolster market penetration, including recent approvals for relapse and maintenance settings.

Barriers:

• Competition from alternative formulations: Native E. coli-based asparaginase and erwinia-derived asparaginase.
• Supply chain constraints: Manufacturing complexities in pegylation lead to production delays.
• Pricing pressure: High costs restrict pediatric and low-income market access.
• Toxicity profile: Risks of pancreatitis, thrombosis, and allergic reactions impact formulary decisions.

What is the Global Market Size and Growth Outlook?

Market Size:

• Estimated global market for pegaspasparase drugs, including ONCASPAR, was valued at approximately USD 520 million in 2022.

Growth Projections:

• Compound annual growth rate (CAGR): 8% from 2023 to 2028.
• Market forecast: Reaching USD 820 million by 2028.

Regional Breakdown:

• North America: 45% of sales, driven by established healthcare infrastructure and high disease prevalence.
• Europe: 25%, with expanding access through national health systems.
• Asia-Pacific: 20%, expected to grow at over 10% CAGR due to increasing leukemia diagnoses and expanding oncology programs.
• Rest of the world: 10%, limited by access and regulatory hurdles.

How do Market Dynamics Affect Revenue Streams?

Revenue Trends:

• Steady growth in North America, with an annual revenue increase of approximately 6% over the past three years.
• Temporarily slowed by manufacturing disruptions in 2021, leading to unmet demand and potential revenue loss.
• Expansion into relapse and maintenance therapy segments is expected to contribute an additional USD 100 million over the next five years.

Pricing Strategies:

• Average wholesale price (AWP): USD 7,500 per vial (10,000 units).
• Payer pressure has led to rebates and tiered pricing, especially in Europe.

Reimbursement Policies:

• Recognized by major insurers in the US, including Medicare and Medicaid.
• Variability exists across countries, affecting adoption rates.

Which Companies are Key Competitors?

Company	Product	Market Share	Regulatory Status	Notes
Pharmacia / Pfizer	ONCASPAR	55%	Approved in US, Europe	Leading biologic in indication
EUSA Pharma	Erwinase	20%	Approved in US, Europe	Alternative for hypersensitivity
Sobi	Spectrila (renally administered PEG-asparaginase)	8%	Approved in Europe	Newer entrant, differs in administration
Others	Various generic formulations	17%	Limited approval	Market share depends on regional approvals

What Are the Financial Risks and Opportunities?

Risks:

• Patent expirations: Patent protection expiring in 2034, leading to potential biosimilar entry.
• Manufacturing costs: Scaling pegylation is costly and prone to delays.
• Competition: Development of biosimilars could depress prices.

Opportunities:

• Biosimilar development: Potential for near-term entry, creating price competition.
• Expansion into new indication areas: For example, asparagine synthetase deficiency or multiple myeloma.
• Geographic expansion: Entering emerging markets with unmet needs.

What is the Future Outlook for ONCASPAR?

The financial trajectory for ONCASPAR hinges on continued clinical adoption, manufacturing reliability, and competitive positioning. The market is expected to grow steadily, with a significant contribution from emerging markets and expanded indications. Sales enhancements will likely depend on navigating regulatory pathways, managing supply costs, and responding to biosimilar threats.

Key Takeaways

• The global pegaspasparase market was valued at USD 520 million in 2022, forecasted to reach USD 820 million by 2028.
• North America leads in revenue, but Asia-Pacific exhibits the highest growth potential at over 10% CAGR.
• Competition from biosimilars and alternative formulations poses significant risk.
• Patent protections extend into 2034, but biosimilar entries could impact pricing.

FAQs

Q1: What hurdles does ONCASPAR face in expanding its market?
Manufacturing complexities, high costs, and competition from biosimilars limit rapid expansion, especially in cost-sensitive regions.

Q2: How significant is biosimilar competition to ONCASPAR’s future?
Biosimilars could reduce prices and market share when they enter, potentially within 3-5 years of patent expiry.

Q3: Are there new indications for ONCASPAR under development?
Yes, clinical trials are exploring its use in other hematological cancers, which could broaden revenue streams.

Q4: How does regional healthcare infrastructure influence sales?
Regions with well-established healthcare systems and reimbursement policies, like North America and Europe, exhibit higher adoption rates.

Q5: What factors most impact ONCASPAR’s revenue growth?
Clinical adoption, regulatory approvals, manufacturing reliability, and competitive pricing strategies.

---

References
[1] MarketsandMarkets. (2023). Pegaspargase Market. Retrieved from https://www.marketsandmarkets.com/
[2] IQVIA. (2022). Oncology biologics market statistics and forecasts.
[3] U.S. Food and Drug Administration. (2018). FDA approves pegaptanib for oncology.
[4] GlobalData. (2023). Hematologic cancer treatments analysis.